Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
PRTC
PRTC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PRTC News
Robert Lyne Appointed CEO of PureTech
Dec 18 2025
Yahoo Finance
PureTech Appoints Robert Lyne as CEO, Focuses on Funding and Innovation
Dec 18 2025
Businesswire
PureTech Appoints Robert Lyne as CEO, Focuses on Funding and Innovation
Dec 18 2025
Newsfilter
Meihua International Medical Technologies, Fly-E Group, and Other Major Stocks Decline in Pre-Market Trading on Monday
Dec 08 2025
Benzinga
PureTech Completes FDA EOP2 Meeting, Advancing LYT-100 for IPF Treatment
Dec 08 2025
Businesswire
PureTech Advances LYT-100 into Phase 3 Clinical Trial Following FDA Feedback
Dec 08 2025
Newsfilter
PureTech's Gallop Oncology Reports 13.2-Month Survival with LYT-200 in AML Phase 1b Trial
Dec 05 2025
Businesswire
Gallop Oncology's LYT-200 Shows Strong Efficacy with 13.2 Months Survival in AML
Dec 05 2025
Newsfilter
PureTech Unveils New Findings from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Reinforcing Its Strong and Lasting Efficacy as a Potential New Standard Treatment for IPF
Sep 29 2025
Newsfilter
CoreWeave, Barrick Mining, FedEx, and Other Major Stocks Rise on Friday
Sep 19 2025
Benzinga
Seaport Therapeutics, a PureTech-founded entity, Moves Second Therapeutic Candidate GlyphAgo™ (SPT-320) into Clinical Development with First Participant Dosed in Phase 1 Study Involving Healthy Volunteers
Sep 11 2025
Newsfilter
Transcript of PureTech (PRTC) Earnings Call for Q2 2025
Sep 02 2025
NASDAQ.COM
Transcript of PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call
Aug 28 2025
Newsfilter
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
Aug 13 2025
Yahoo Finance
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
Jul 17 2025
Newsfilter
PureTech Health CEO Bharatt Chowrira Steps Down; Names Robert Lyne Interim CEO
Jul 16 2025
NASDAQ.COM
Show More News
